(Reuters) – AstraZeneca Plc said on Monday the U.S. Food and Drug Administration (FDA) rejected its asthma medicine, Fasenra, for treatment of chronic rhinosinusitis with nasal polyps, a condition where benign growths can cause pain and stuffiness.
The London-listed drugmaker said the FDA had issued a issued a complete response letter following its application to extend use of the drug and requested additional clinical data from AstraZeneca.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Rashmi Aich)
